Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Technilab Pharma Inc. has accepted an $80-million takeover bid from German drug giant Merckle GmbH, saying it was motivated by competition in the generic drug sector and the need to get larger.

In response to the $6.10-a-share bid yesterday, Technilab shares jumped 25 per cent or $1.20 to $6 on the Toronto Stock Exchange.

"There is no question that the marketplace has recently become very competitive and has negatively impacted the company's recent financial results," Technilab president and chief executive officer Jacques Boisvert said in a statement.

Story continues below advertisement

For the second quarter ended Feb. 29, Montreal-based Technilab posted a loss of $295,000 or 2 cents a share, compared with a profit of $1.4-million or 11 cents a year earlier. The company also lost money in the first quarter.

"We realize that success in the generic pharmaceutical industry is more than ever driven by critical mass and rapid market penetration," he said, adding that Merckle has an extensive understanding of the industry and the resources to support Technilab's future growth.

Claude Camiré, an analyst with Dundee Securities Inc., said provincial health insurance plans have limited the prospects for higher generic drug prices. "While new products can improve margins, these seem to erode quickly," he said, adding that in the face of weaker prices, costs continue to rise.

Mr. Camiré said Technilab also has been struggling to integrate its acquisition last year of AltiMed Pharmaceutical Co. of Mississauga.

Vincent Taillefer, a spokesman for Technilab, said the weak market has made it difficult for the company to continue financing its growth, especially in the United States.

The acquisition of Technilab would continue a consolidation trend that has been sweeping the pharmaceutical industry around the globe.

Earlier this year, Novopharm Ltd. of Toronto said the need to team up with a stronger company in order to remain competitive prompted its decision to be acquired by Israel's Teva Pharmaceutical Industries Ltd. for $285-million (U.S.) in stock.

Story continues below advertisement

Technilab said certain members of the Sabourin family, who own about 65 per cent of the 13.2 million outstanding shares of Technilab, have entered into a lock-up deal with Merckle and have agreed to irrevocably tender their shares to the offer.

In addition, the company said it has received an opinion from Wasserstein Perella & Co. Inc. of New York that the offer is fair to shareholders from a financial point of view. As a result, the Technilab board has agreed to support the offer.

Under the accord, Technilab would become a unit of Merckle's generic arm, Ratiopharm GmbH.

Report on Business Company Snapshot is available for:
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies